ORY-1001

Generic Name: ORY-1001

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₄N_₂

CAS Number: 1401966-39-9

Unique Ingredient Identifier: XC0UT08SNJ

Associated Conditions: -

Associated Therapies: -

Clinical Trials

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2024

Oryzon Genomics reports financial results for Q3 2024, highlights PORTICO Phase IIb trial data for vafidemstat in BPD, FDA approval for PORTICO-2 Phase III trial, strengthened IP position for vafidemstat, and first cohort dosed in Phase Ib study of iadademstat in first-line AML. R&D expenses reduced by $5.1M.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy